Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
SOPH · against 477 other Healthcare companies of similar size
Ranked #311 of 478 · scores higher than 12% of peers
Bars: peers in each 10-point band of the valuation score168 peers with a valuation score of 0–9, including SOPH · Click a bar to see the companies
Mainly because of its earnings yield, EBITDA yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | SOPH | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 466 reported | -16.8% | 0.6% | 15% | 30% | |
| EBITDA yieldHigher is better · 483 reported | -13.2% | 3.5% | 16% | 50% | |
| Free cash flow yieldHigher is better · 202 reported | -8.6% | -4.9% | 40% | 20% | |
| Book yieldHigher is better · 478 reported | 14.1% | 45.6% | 13% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 311 | 519M USD | 8 | 22 | |
| 311 | 1.2B USD | 8 | 40 | |
| 311 | 1.1B USD | 8 | 50 | |
| 311 | 673M USD | 8 | 35 | |
| 311 | 588M USD | 8 | 24 | |
| 311 | 303M USD | 8 | 27 | |
| 311 | 354M USD | 8 | 13 | |
| 311 | 467M USD | 8 | 44 | |
| 311 | 549M USD | 8 | 30 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score